Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells

Lapatinib, a small molecule ErbB2/EGFR inhibitor, is FDA-approved for the treatment of metastatic ErbB2-overexpressing breast cancer; however, lapatinib resistance is an emerging clinical challenge. Understanding the molecular mechanisms of lapatinib-mediated anti-cancer activities and identifying r...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ming, Howard, Erin W., Parris, Amanda B., Guo, Zhiying, Zhao, Qingxia, Ma, Zhikun, Xing, Ying, Liu, Bolin, Edgerton, Susan M., Thor, Ann D., Yang, Xiaohe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601698/
https://www.ncbi.nlm.nih.gov/pubmed/28938602
http://dx.doi.org/10.18632/oncotarget.19375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601698/
https://www.ncbi.nlm.nih.gov/pubmed/28938602
http://dx.doi.org/10.18632/oncotarget.19375

Ejemplares similares